February 24, 2015

Not intended for U.S. and UK Media

ASCO GU 2015 to Feature Latest Oncology Research from Bayer

Includes data from studies evaluating radium-223 dichloride, sorafenib and investigational agent ODM-201
Abstracts: 160, 182, 195, 202, 230, 247, 253, 254, 403

Berlin, February 24, 2015
- Bayer HealthCare announced today that new data from
its oncology portfolio will be presented at the 2015 Genitourinary Cancers
Symposium of the American Society of Clinical Oncology (ASCO GU) taking place
February 26 - 28 in Orlando, FL (USA). The presentations will include data on
Xofigo® (radium-223 dichloride) and Nexavar® (sorafenib), as well as ODM-201,
an investigational therapy Bayer is jointly developing with Orion Corporation.

Notable studies evaluating Bayer's products and pipeline candidates at ASCO GU
2015 are listed below:

Radium-223 Dichloride (radium-223)
- Effect of radium-223 dichloride (Ra-223) on pain from US EAP
o Abstract 160, Board G22, General Poster Session A: Prostate Cancer
o Thursday, February 26, 11:30 AM - 1:00 PM (EST)
- External beam radiation therapy (EBRT) use and safety with radium-223
dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer
(CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
o Abstract 182, Board H18, General Poster Session A: Prostate Cancer
o Thursday, February 26, 11:30 AM - 1:00 PM (EST)
- 3-Year Safety Follow-up of Radium-223 Dichloride (Ra-223) in Patients (Pts)
With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone
Metastases (Mets) From ALSYMPCA
o Abstract 195, Board J5, General Poster Session A: Prostate Cancer
o Thursday, February 26, 11:30 AM - 1:00 PM (EST)
- Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on
prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in
patients (pts) with castration-resistant prostate cancer (CRPC) and bone
metastases (mets): A phase 1/2a clinical trial
o Abstract 202, Board J12, General Poster Session A: Prostate Cancer
o Thursday, February 26, 11:30 AM - 1:00 PM (EST)
- Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP)
o Abstract 247, Board C16, General Poster Session B: Prostate, Penile,
Testicular, and Urethral Cancers, and Urothelial Carcinoma
o Friday, February 27, 12:15 - 1:45 PM (EST)
- Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an
expanded access setting
o Abstract 253, Board C22, General Poster Session B: Prostate, Penile,
Testicular, and Urethral Cancers, and Urothelial Carcinoma
o Friday, February 27, 12:15 - 1:45 PM (EST)
- Effect of radium-223 dichloride (Ra-223) on risk for and duration of
hospitalization in ALSYMPCA by docetaxel (D) subgroup
o Abstract 254, Board C23, General Poster Session B: Prostate, Penile,
Testicular, and Urethral Cancers, and Urothelial Carcinoma
o Friday, February 27, 12:15 - 1:45 PM (EST)


Sorafenib
- Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for
unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial
o Abstract 403, Board B1, General Poster Session C: Renal Cell Cancer
o Saturday, February 28, 7:00 AM - 7:55 AM (EST)

ODM-201
- Pharmacokinetics, activity and safety of ODM-201 in chemotherapy-naïve
patients with metastatic castration resistant prostate cancer: An open-label
phase I trial with long-term extension
o Abstract 230, Board B24, General Poster Session B: Prostate, Penile,
Testicular, and Urethral Cancers, and Urothelial Carcinoma
o Friday, February 27, 12:15 - 1:45 PM (EST)


About Radium-223 Dichloride (Xofigo®)

Radium-223 dichloride (radium-223) is a therapeutic alpha particle-emitting
pharmaceutical with an anti-tumor effect on bone metastases. Radium-223 mimics
calcium and selectively targets bone, specifically areas of bone metastases, by
forming complexes with the bone mineral hydroxyapatite. The high linear energy
transfer of alpha emitters leads to a high frequency of double-strand DNA
breaks in adjacent tumor cells, resulting in a potent cytotoxic effect. The
alpha particle range from radium-223 is less than 100 micrometers, which
minimizes damage to the surrounding normal tissue.

Radium-223 dichloride has been approved under the brand name Xofigo® in more
than 40 countries worldwide, including the U.S. and the EU. In Europe, it is
approved for the treatment of adults with CRPC, symptomatic bone metastases and
no known visceral metastases.

About Sorafenib (Nexavar®)

Sorafenib, an oral anti-cancer therapy, is approved under the brand name
Nexavar® in more than 100 countries worldwide. In Europe, Nexavar is approved
for the treatment of hepatocellular carcinoma (HCC); for the treatment of
patients with advanced renal cell carcinoma (RCC) who have failed prior
interferon-alpha or interleukin-2 based therapy or are considered unsuitable
for such therapy; and for progressive, locally advanced or metastatic,
differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma,
refractory to radioactive iodine.

In preclinical studies, sorafenib has been shown to inhibit multiple kinases
thought to be involved in both cell proliferation (growth) and angiogenesis
(blood supply) - two important processes that enable cancer growth. These
kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and
RET.

Nexavar is co-developed by Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and
Bayer, except in Japan where Bayer manages all development. The companies
co-promote Nexavar in the U.S. Outside of the U.S., excluding Japan, Bayer has
exclusive marketing rights, and Bayer and Onyx share profits globally.

About ODM-201

ODM-201 is an investigational novel androgen receptor (AR) antagonist with
unique chemistry that is designed to block the growth of prostate cancer cells.
ODM-201 binds to the AR with high affinity and inhibits receptor function. In
nonclinical models, ODM-201 has shown to only minimally penetrate the
blood-brain barrier.

In 2014, Bayer and Orion had entered into a global agreement under which they
will jointly develop ODM-201, with Bayer contributing a major share of the
costs of future development. Bayer will commercialize ODM-201 globally and
Orion has the option to co-promote ODM-201 in Europe. Orion will be responsible
for the manufacturing of the product.

About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a
portfolio of innovative treatments. The oncology franchise at Bayer now
includes three oncology products and several other compounds in various stages
of clinical development. Together, these products reflect the company's
approach to research, which prioritizes targets and pathways with the potential
to impact the way that cancer is treated.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's
leading, innovative companies in the healthcare and medical products industry
and is based in Leverkusen, Germany. The company combines the global activities
of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals
divisions. Bayer HealthCare's aim is to discover, develop, manufacture and
market products that will improve human and animal health worldwide. Bayer
HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is
represented in more than 100 countries. More information is available at
www.healthcare.bayer.com.

Our online press service is just a click away: press.healthcare.bayer.com
Follow us on Facebook: http://www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerHealthCare

Find more information at www.bayerpharma.com.

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.